Home
Deutsch
Advanced Search
Browse by ...
Publication overview
Contact persons
Help
DOI
 |
|
as soon as is submitted to ZB.
Nanoparticles for controlled delivery of siRNA.
In:. 2024. 332-351 (Nanomedicine, Nanotheranostics and Nanobiotechnology: Fundamentals and Applications)
Molecular therapy with small interfering ribonucleic acid (siRNA therapeutics) has demonstrated enormous clinical potential against a variety of fatal pathologies caused by atypical gene overexpression or genetic mutation. Significant progress has been made in siRNA-based therapeutics in an astonishingly short period of time. It is extremely difficult to explore the full potential of such gene-based therapeutic approaches without ensuring the safe and effective delivery of SiRNA to the target sites. Due to various limitations associated with viral-based approaches and limited or slow progress in non-viral counterpart development, the current methods of siRNA delivery materials and their diversity remain limited. This chapter elaborates on the importance of siRNA in disease management, as well as the evolution of nanoparticle systems in the efficient transfer of siRNA to target sites, which leads the technology to clinical application. The classification of siRNA nanocarriers and the rationale underlying the application of these nanocarrier systems that have been studied so far are specifically discussed.
Altmetric
Additional Metrics?
Edit extra informations
Login
Publication type
Article: Edited volume or book chapter
ISSN (print) / ISBN
[9781040096697, 9780367655495]
Conference Title
Nanomedicine, Nanotheranostics and Nanobiotechnology: Fundamentals and Applications
Quellenangaben
Pages: 332-351
Non-patent literature
Publications
Institute(s)
Institute of Lung Health and Immunity (LHI)